Sales of Biogen’s costly new Alzheimer’s drug fall far short of expectations.

The drug, Aduhelm, brought in $300,000 in revenue in its first full three months of availability. The company expects the drug to generate minimal revenue for the rest of the year.

View original article
Contributor: Rebecca Robbins